Simnotrelvir/Ritonavir

Effects and efficacy:
For the treatment of adult patients with mild to moderate novel coronavirus infection (COVID-19).
Dosage and administration:
Oral administration, on an empty stomach. Tablets must be swallowed whole and must not be chewed, broken or crushed. This product is a combination of sennotevir tablets and ritonavir tablets. Sennotevir must be taken with ritonavir. If not taken with ritonavir, the plasma level of sennotevir may not be sufficient to achieve the desired therapeutic effect. It should be used as soon as possible within 3 days or less of the first onset of symptoms. The recommended dose is sennotevir 0.750 g (2 tablets) combined with ritonavir 0.1 g (1 tablet), taken orally once every 12 hours for 5 consecutive days. Special populations Hepatic impairment This product has not yet been clinically studied in subjects with hepatic impairment. Ritonavir is mainly metabolized and cleared by the liver, and patients with severe hepatic insufficiency should not use this product. Renal impairment This product has not yet been clinically studied in subjects with renal impairment.
Adverse reactions:
Possible adverse reactions of Senotegravir Tablets/Ritonavir Tablets: Metabolic and nutritional diseases: dyslipidemia, hyperuricemia. Gastrointestinal system diseases: common diarrhea, nausea; occasional vomiting, abdominal distension. Skin and subcutaneous tissue diseases: itching, rash. Heart disease: sinus bradycardia. Other abnormal examination indicators: decreased neutrophil count, increased blood creatine phosphatase, decreased platelet count.
Drug contraindications:
Allergic to this product is prohibited during pregnancy.